Thumbs Up/Thumbs Down: The new buzz in R&D, blockbuster work on a budget and why what’s dead may never die
Endpoints assesses the big biopharma R&D stories of the week, with a little added commentary on what they mean for the industry.
Bioelectronics gets a star turn
Let’s get it out front. I have a weakness for big thinking about new R&D fields. So when I got wind of the tie-up between GlaxoSmithKline and Verily (Lord Google’s life science arm), I got up at 3 am and wrote the story. The idea that nanotech based devices can be used to orchestrate a series of electric pulses to treat a disease can only thrill a real R&D enthusiast. And at this stage, everything has great potential. We’re a couple of years out from proof of concept, so this is far from a commercial story. (Which, let’s face it, is what GSK really needs now.) Science lovers will follow it as closely as they can. Count me in.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters